Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR in Pediatric Hypothalamic Obesity
NCT00076362Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2004
- Primary completion
- Jul 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of octreotide in hypothalamic obesity (HO), sponsored by Novartis. Started Mar 2004; status: completed.
02
Drugs
octreotide
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT00076362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076362.